logo
 
Products 

BRaf codon 600/601 assay kits

Assay Reagent Kits> KRas codon 12/13 mutations > BRaf codon 600 mutations > HBV DNA & mutationsPlasmids

 

BRAF V600E mutation is associated with about 50% of malignant melanomas, almost all of the Hairy Cell Leukemia cases, and certain thyroid tumors and colon cancers.  V600E mutation locks the BRAF protein at the activated state, leading to uncontrolled cell growth. Vemurafenib is a BRAF kinase inhibitor that has been approved by FDA in August 2011 for use in malignant melanomas bearing BRAF V600E mutation.

Of all the BRAF V600 mutations, V600E accounts for 73-79%, V600K accounts for 12-20%, and other mutations (such as V600R and V600M) about 6-9%.  Recent studies show that these non-V600E mutations, including K601E mutation, may also respond to Vemurafenib treatment.  Some of these mutations are associated with different prognoses.  Thus, it is desirable that a BRAF V600 mutation test is capable of detecting all the potential V600 and K601 mutations with high specificity and sensitivity.

 

BRaf V600E mutation MS kit

This assay detects BRaf V600E (T1799A) mutation (codon GTG to GAG) using a mutant specific primer approach.  Sensitivity is at 1%.

Cat #  AK-012

 

BRaf V600E mutation MSHS kit

This assay detects BRaf V600E (T1799A) mutation (codon GTG to GAG) using a mutant specific primer approach combined with a sensitivity-enhancing reagent.  Sensitivity is at 0.1%.

Cat #  AK-014

 

BRaf codon 600/601 mutant enrichment and sequencing kit

This kit allows detection of BRaf codon 600/601 mutations by PCR-sequencing at a much higher sensitivity (~0.5%) than direct sequencing.

Cat #  AK-018

 

 

 
   
copy right © 2008 - 2013, Reniguard Life Sciences Inc, all rights reserved